#ModernaQ3VaccineSales Moderna (MRNA) will report Q3 results before the US market open on Nov 6. It posted a net loss of ~$800M in Q2. Q3 vaccine sales will shed light on seasonal vaccination demand and revenue trends, while cash burn and progress in mRNA cancer therapies will offer clues to future growth. #MNAUSDT$